

Foster, Claire and Haviland, Joanne and Winter, Jane and Grimmett, Chloe and Chivers Seymour, Kim and Calman, Lynn and Corner, Jessica and Din, Amy and Fenlon, Deborah and May, Christine M. and Smith, Peter W. and Richardson, Alison (2016) The impact of primary colorectal cancer treatment on physical symptoms and functioning in the first two years: results from the ColoREctal Wellbeing (CREW) cohort study. In: The British Psychosocial Oncology Society 2016 conference, 3-4 March 2016, Cambridge, UK. (Unpublished)

Access from the University of Nottingham repository:

http://eprints.nottingham.ac.uk/32432/1/CREW%20impact%20of%20primary%20colorectal %20cancer%20treatment%20BPOS%202016%20abstract%20oral.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the University of Nottingham End User licence and may be reused according to the conditions of the licence. For more details see: http://eprints.nottingham.ac.uk/end user agreement.pdf

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

The impact of primary colorectal cancer treatment on physical symptoms and functioning in the first two years: results from the ColoREctal Wellbeing (CREW) cohort study

Claire Foster, Joanne Haviland, Jane Winter, Chloe Grimmett, Kim Chivers Seymour, Lynn Calman, Jessica Corner, Amy Din, Deborah Fenlon, Christine M May, Peter W Smith, Alison Richardson, Members of CREW Study Advisory Committee*

*Members of Study Advisory Committee: Julia Addington-Hall, Jo Armes, Janis Baird, Andrew Bateman, Nick Beck, Graham Moon, Claire Hulme, Karen Poole, Susan Restorick-Banks, Paul Roderick, Claire Taylor, Jocelyn Walters, Fran Williams

Background

Cancer and its treatment can have a considerable long-term impact. Relatively little is known about what this means in relation to health and wellbeing, how to prepare patients for what to expect, and to tailor support.

Aims

Describe the impact of colorectal cancer treatment and patient characteristics including self-efficacy (confidence to self-manage illness-related problems) on symptoms and functioning following curative intent surgery.

Methods

857 colorectal cancer patients (Dukes' A-C) recruited 2010-2012 from 29 UK centres. Questionnaires pre-surgery (baseline), 3, 9, 15, 24 months included assessments of symptoms, functioning and patient characteristics. Regression analyses assessed change in functioning and symptoms over time and associations with socio-demographic, clinical, treatment and pre-surgery psychosocial characteristics.

Results

Most problematic symptoms over follow-up: impotence (45% moderate/severe problems at 24 months), urinary frequency (34%), fatigue (24%), stool frequency (22%), insomnia (20%), flatulence (20%) and pain (16%). Symptoms worsened immediately following surgery and then most improved significantly, generally from 15 months; although some remained as prevalent (impotence and flatulence). Urinary incontinence significantly worsened (mostly changes from none to mild symptoms). From multiple regression, risk factors consistently statistically significantly associated with worse symptoms and poorer functioning were, worse depression and lower self-efficacy at baseline, more co-morbidities and having a stoma. Tumour site, neo-adjuvant and adjuvant treatment had little effect.

Conclusions

Most symptoms improve by 15 months following colorectal cancer treatment although some persist. Pre-surgery self-efficacy and depression are important predictors of symptoms and functioning, independent of clinical and treatment factors, and amenable to interventions to improve recovery.

Acknowledgements

CREW is funded by Macmillan Cancer Support